FAGRON a.s. - Continued strong third quarter performance with 11% topline growth

Continued strong third quarter performance with 11% topline growth to €191 million

Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2023.

Key Highlights

• Solid revenue growth continues with 10.6% reported growth (13.9% at CER) and 10.2% organic growth (13.4% at CER) to €191.4 million
• Sustained strong performance in North America and solid recovery of Latin America; EMEA reflects completion of pricing pass through
• Roll out of global operational excellence initiatives continues
• Signing of Parma Produkt acquisition provides entry into attractive Hungarian compounding market
• Science Based Targets initiative (SBTi) has approved our near-term science-based emission reduction target
• FY 2023 revenue between €750-€770 million; improvement in profitability YoY

Full press release